Committed to transforming the lives of patients with pulmonary diseases

Pulmovant is developing innovative therapies, beginning with mosliciguat, to transform the treatment paradigm for people suffering from pulmonary diseases.

Mosliciguat aims to provide an effective, once-daily, inhaled treatment option for patients with pulmonary diseases.

Mosliciguat has the potential to be first-in-class with a differentiated sGC activation mechanism.

Pulmovant is singularly focused on pulmonary diseases and is committed to delivering benefit to patients with these unique needs.